The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALLOGENE THERAPEUTICS INC | COM | 019770106 | 6,221,276 | 2,920,787 | SH | SOLE | 2,920,787 | 0 | 0 | ||
FRONTIER GROUP HLDGS INC | COM | 35909R108 | 199,516,206 | 28,061,351 | SH | SOLE | 28,061,351 | 0 | 0 | ||
GITLAB INC | CLASS A COM | 37637K108 | 642,334 | 11,399 | SH | SOLE | 11,399 | 0 | 0 | ||
KRONOS BIO INC | COM | 50107A104 | 1,233,061 | 1,297,959 | SH | SOLE | 1,297,959 | 0 | 0 | ||
PROCORE TECHNOLOGIES INC | COM | 74275K108 | 606,558 | 8,095 | SH | SOLE | 8,095 | 0 | 0 | ||
RLX TECHNOLOGY INC | SPONSORED ADS | 74969N103 | 38,979,781 | 18,046,195 | SH | SOLE | 18,046,195 | 0 | 0 | ||
SILEXION THERAPEUTICS CORP | SHS NEW | G1281K122 | 227,990 | 113,428 | SH | SOLE | 113,428 | 0 | 0 | ||
UROGEN PHARMA LTD | COM | M96088105 | 5,278,204 | 495,606 | SH | SOLE | 495,606 | 0 | 0 |